This review summarizes recent advances in understanding the genetic basis of cancer and their translation into personalized medicine.  Significant progress has been made in identifying driver mutations and characterizing the complex interplay of genetic alterations within individual tumors. Next-generation sequencing technologies have enabled comprehensive genomic profiling, revealing diverse mutational landscapes across cancer types. This wealth of genomic data fuels the development of targeted therapies, including kinase inhibitors and immunotherapies, which are designed to exploit specific genetic vulnerabilities within a patient's tumor.  While significant clinical benefits have been observed in specific cancers, challenges remain, including the emergence of resistance mutations, the identification of actionable targets in genomically heterogeneous tumors, and the need for improved predictive biomarkers.  Furthermore, ethical considerations regarding data privacy and accessibility must be addressed. Future research directions include refining our understanding of tumor microenvironment genetics, incorporating epigenetic and transcriptomic data, and developing more effective strategies to combat treatment resistance. Ultimately, a deeper understanding of cancer genetics will continue to drive the evolution of personalized cancer medicine, leading to more effective and less toxic therapies tailored to individual patients.